Farnesyltransferase inhibitors and myeloid malignancies: Phase I evidence of Zarnestra activity in high-risk leukemias

Seminars in Hematology

Volumn 39, Issue 3 SUPPL. 2, 2002, Pages 31-35

  Lancet, Jeffrey E ^a,b,c   Rosenblatt, Joseph D ^a,b,c   Karp, Judith E ^a,b,c,d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d Box 610 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; TRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; ATAXIA; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEVER; HIGH RISK POPULATION; HUMAN; INFECTION; MYELOID LEUKEMIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POLYDIPSIA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING; ACUTE DISEASE; DRUG ANTAGONISM; DRUG EFFECT; LEUKEMIA; MYELODYSPLASTIC SYNDROME; REVIEW; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; LEUKEMIA; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION;

EID: 0036656207     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.35985     Document Type: Article

References (21)

1. Therapy of acute myeloid leukemia
2. Clinical and biological activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial
3. The challenge of acute myeloid leukemia in older patients
4. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
5. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
6. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
7. Farnesyltransferase inhibitors define a role for Rho B in controlling neoplastic pathophysiology
8. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
9. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs
10. PI3K: Downstream AKTion blocks apoptosis
11. ERK2 and Phospho-ERK2 are prognostic for survival in AML and complement the prognostic impact of Bax and BCL-2
12. Differences in the expression of signal transduction molecules between normal and leukemic bone marrow
13. Characterization of the antitumor effects of the selective farnesyltransferase inhibitor R 115777 in vivo and in vitro
14. Clinical activity with the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer-Relationship with tumour pheno-type
15. A phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with gemcitabine (gem)
16. Phase II trial of R115777 in patients with recurrent malignant glioma not taking enzyme inducing antiepileptic drugs (EIAED)
17. Effects of farnesyl transferase inhibitor R115777 on hematopoiesis, leukemic cell proliferation, and signaling through the nitrogen-activated protein kinase (MAPK) pathway
18. Interim results from a phase II study of R115777 (ZARNESTRA) in patients with relapsed and refractory acute myelogenous leukemia
19. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine